Cardiovascular biopharma specialist Amarin (Nasdaq: AMRN) and four independent physicians have filed a law suit to permit off-label promotion.
The law suit, filed in the District Court for the Southern District of New York, seeks a judicial declaration that Food and Drug Administration regulations limiting off-label promotion are unconstitutional under the First and Fifth Amendments. It relates specifically to Amarin’s proposed promotion of its triglyceride-reducing drug Vascepa (icosapent ethyl).
The physicians in the suit say they have First Amendment rights to receive truthful and non-misleading information from Amarin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze